Funding Rounds
ExeVir Bio

ExeVir Bio Debt Financing (2023, $26M)

ExeVir Bio

Novel antibody therapies for people who can't get vaccinated.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Debt Financing

Raised Amount: $26.86M

Raised Date: 2023-09-01

Investors